Analysis: Alkermes aims at 'Big Biotech' status with EDT buyout

Xconomy examines Alkermes' ($ALKS) new company strategy in the wake of its acquisition of Elan Drug Technologies. The EDT buyout, explains Luke Timmerman, gives the biotech a steady revenue flow to build on with some prospective upside from products like Bydureon. And by limiting its borrowing to $450 million, says CEO Richard Pops, the company obtained good terms and a shot at an early payback. "Leveraging a [money-losing] biotech company is reckless, but leverage for a cash-flow positive and stable company is prudent balance sheet management," Pops says. Article

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.